| Code | CSB-RA884474MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody targets CDCP1 (CUB domain-containing protein 1), a transmembrane glycoprotein that plays critical roles in cell adhesion, migration, and survival signaling. CDCP1 functions as a substrate for Src family kinases and becomes activated through proteolytic cleavage, promoting downstream signaling pathways involved in cellular motility and metastasis. Overexpression of CDCP1 has been documented in multiple cancer types, including lung, breast, pancreatic, and colorectal carcinomas, where it correlates with aggressive disease progression, metastatic potential, and poor clinical outcomes. Its involvement in cancer cell dissemination and resistance to therapeutic agents makes it a significant target in oncology research.
This antibody is produced as a research-grade biosimilar to the reference antibody described in patent US20200181281A1, maintaining comparable specificity and binding characteristics. It serves as a valuable research tool for investigating CDCP1 expression patterns, studying its role in tumor biology and metastatic mechanisms, and exploring potential therapeutic interventions targeting CDCP1-mediated signaling pathways in various cancer models.
There are currently no reviews for this product.